SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.

BMC Endocr Disord · 2019 · PMC6580491 · PMID 31208401

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Due to the failure to meet earlier endpoints, these renal outcomes were exploratory only in the two trials, but nevertheless both suggested a strong trend towards a protective effect with treatment, with 40% reduction in the CANVAS Program (HR 0.60; 95% CI 0.47–0.77) and 47% reduction in DECLARE-TIMI 58 (HR 0.53; 95% CI 0.43–0.66).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.